Management of adverse events following treatment with anti-programmed death-1 agents

Oncologist

Volumn 21, Issue 10, 2016, Pages 1230-1240

  Weber, Jeffrey S ^a   Postow, Michael ^b,c   Lao, Christopher D ^d   Schadendorf, Dirk ^e  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Drug related side effects and adverse reactions; Melanoma; Nivolumab; Pembrolizumab; Programmed cell death 1 receptor

Indexed keywords

ACID LIPASE; ALANINE AMINOTRANSFERASE; AMYLASE; ASPARTATE AMINOTRANSFERASE; AUTOANTIBODY; BILIRUBIN; C REACTIVE PROTEIN; CORTICOSTEROID; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA GLUTAMYLTRANSFERASE; INFLIXIMAB; IPILIMUMAB; LACTATE DEHYDROGENASE; MESALAZINE; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; VEMURAFENIB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMENORRHEA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BIOPSY; BLOATING; BRONCHOSCOPY; CELL CYCLE CHECKPOINT; COLITIS; COLONOSCOPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DEPRESSION; DIARRHEA; DISEASE ONTOLOGY; ENTERITIS; EOSINOPHILIA; ERECTILE DYSFUNCTION; ESOPHAGITIS; FATIGUE; FOLLOW UP; HUMAN; HYPOGLYCEMIA; HYPOPHYSITIS; HYPOTHYROIDISM; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LIVER TOXICITY; LUNG NODULE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MELANOMA; MONOTHERAPY; MYDRIASIS; PANCREATITIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PRURITUS; PULSE OXIMETRY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; ULTRASOUND; VISUAL SYSTEM EXAMINATION; ANTAGONISTS AND INHIBITORS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CTLA-4 ANTIGEN; HUMANS; MELANOMA; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84991702512     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2016-0055     Document Type: Article

References (21)

1. Hodi FS, O’Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363: 711-723
2. Robert C, Long GV, Brady B et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372:320-330
3. Weber JS, D’Angelo SP, Minor D et.al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015;16: 375-384
4. Robert C, Schachter J, Long GV et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl JMed 2015;372:2521-2532
5. Postow MA, Chesney J, Pavlick AC et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015;372: 2006-2017
6. Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373: 23-34
7. Yervoy (ipilimumab) [package insert]. Princeton, NJ: Bristol-Myers Squibb Co.; 2013
8. Opdivo (nivolumab) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Co.; 2014
9. Keytruda (pembrolizumab) [prescribing information]. Kenilworth, NJ: Merck & Co., Inc.; 2015
10. Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015;373: 123-135
11. Paz-Ares L, Horn L, Borghaei H et al. Phase III, randomized trial (CheckMate 057) of nivolumab versus docetaxel in advanced non-squamous (non- SQ) cell non-small cell lung cancer (NSCLC). Poster presented at: American Society of Clinical Oncology 2015 Annual Meeting; May 29-June 2, 2015; Chicago, IL.
12. Bauer TM, McCleod M, Chandler JC et al. A phase IIIb/IV safety trial of nivolumab (NIVO) in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed during or after receiving at least one prior systemic regimen. Poster presented at American Society of Clinical Oncology 2015 AnnualMeeting;May 29-June 2, 2015; Chicago, IL.
13. Motzer RJ, Rini BI, McDermott DF et al. Nivolumab for metastatic renal cell carcinoma: Results of a randomized phase II trial. J Clin Oncol 2015;33:1430-1437
14. Hodi FS, Postow MA, Chesney J et al. Clinical response, PFS and safety in patients with advanced melanoma receiving nivolumab combined with ipilmumuab versus ipilimumab monotherapy in CheckMate 069 study. Poster presented at: American Society of Clinical Oncology 2015 AnnualMeeting; May 29-June 2, 2015; Chicago, IL.
15. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute.CommonTerminology Criteria forAdverse Events (CTCAE). Version 4.03. Available at http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference:5x7.pdf. Accessed February 8, 2016
16. Sundar R, Cho BC, Brahmer JR et al. Nivolumab in NSCLC: Latest evidence and clinical potential. Ther Adv Med Oncol 2015;7:85-96
17. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-2454
18. Naidoo J, Page DB, Li BT et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 2015;26:2375-2391
19. Robert C, Ribas A, Wolchok JD et al. Antiprogrammed- death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial. Lancet 2014;384:1109-1117
20. Weber JS, Antonia SJ, Topalian SL et al. Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): A pooled analysis. J Clin Oncol 2015;33(suppl):9018a.
21. Bristol-Myers Squibb Company. Risk Evaluation andMitigation Strategy (REMS). Initial REMS approval: 03/2011; most recent modification: 02/2012.Available at http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsand-Providers/UCM249435.pdf. Accessed February 8, 2016.